Novel N-cadherin expression has been linked to the invasive phenotype in bladder tumors yet a primary role for N-cadherin in invasion has not been defined in this model. To address this, N-cadherin was stably transfected into E-cadherin expressing bladder carcinoma cells. This resulted in an enhanced invasive capacity in in vitro assays that was blocked by incubation with an N-cadherin function-blocking antibody in a dose-dependent manner. Analysis of the signaling pathway(s) implicated in N-cadherin-mediated invasion in bladder carcinoma cell lines revealed no correlation between MAPK signaling and invasion, in the presence or absence of fibroblast growth factor 2. Also, while MAPK and p38 kinase inhibitors did not alter the invasive behavior of these cells, an increase in the phosphorylation of Akt at serine-473 was detected in N-cadherin transfectants, suggestive of N-cadherin-mediated Akt activation in bladder cell invasion. Incubation of N-cadherin transfectants with either PI3 kinase or Akt inhibitors resulted in a significant decrease in the invasive capacity of these cells. Exposure of cells to PP2, a src family kinase inhibitor, also decreased the invasive potential of N-cadherin transfectants and resulted in reduced phosphorylation of Akt. The involvement of Akt signaling in bladder cell invasion was also supported by the inhibition of bladder cell invasion by cells constitutively expressing an activated Akt kinase, using the PI3 kinase and Akt inhibitors and PP2. These results suggest that activation of PI3/AKT kinase following N-cadherin expression contributes to the increased invasive potential of bladder carcinoma cells.
Introduction
The cadherins are a family of calcium-dependent, cellcell adhesion molecules that have been implicated in the invasive process. The most extensively studied member, E-cadherin, has been reported by numerous groups to play an invasive-suppressor role (Frixen et al., 1991; Vleminckx et al., 1991) . Loss or reduced expression of E-cadherin was detected in different cancers and in bladder cancer is correlated with increased invasive potential and poor survival (Bringuier et al., 1993; Kawakita et al., 1994; Hong et al., 1995; Lipponen and Eskelinen, 1995; Miyazaki et al., 1995; Mialhe et al., 1997) . Loss of E-cadherin, however, does not necessarily indicate an absence of cadherin expression since alternative cadherin family members are expressed in different tumor types. We have previously identified aberrant expression of N-cadherin associated with the invasive phenotype in bladder carcinoma cells and concluded that N-cadherin does not play an invasive-suppressor role in bladder cancer (Gee et al., 1998) . Subsequently, this observation was confirmed by Giroldi et al. (1999) in an alternative panel of bladder carcinoma cell lines and has also been reported in breast (Hazan et al., 1997) , prostate and melanoma (Hsu et al., 1996; Li et al., 2001 ) cell lines.
In human breast carcinoma cell lines, E-and Ncadherin are mutually exclusive where cell lines expressing N-cadherin displayed a fibroblast morphology (Hazan et al., 1997) . Transfection of N-cadherin in breast tumor cells induced cell migration, invasion and metastasis in a dominant fashion since the migratory behavior was elicited even when N-cadherin was coexpressed with E-cadherin (Nieman et al., 1999; Hazan et al., 2000) . More recently, Suyama et al. (2002) demonstrated that in the presence of N-cadherin, FGF-2 caused sustained activation of the MAPK-ERK pathway, resulting in MMP-9 gene transcription and tumor cell invasion.
In an earlier study, we reported that mutual exclusivity of E-and N-cadherin expression in bladder carcinoma cell lines is not necessarily the case (Gee et al., 1998) . Instead, we have identified numerous bladder cell lines that coexpress E-, P-and N-cadherin, a cadherin expression profile recently confirmed to occur in human bladder tumors (Rieger-Christ et al., 2001) . In light of the fact that breast and bladder carcinoma cells often express different cadherin profiles, the goal of this study was to elucidate the role of N-cadherin in bladder cancer and examine the signaling pathway(s) activated by this cadherin family member. Towards this end, we have successfully transfected N-cadherin into bladder carcinoma cell lines normally expressing E-cadherin and have demonstrated that N-cadherin promotes invasion in these cells. In addition, we show that the invasive phenotype acquired in N-cadherin expressing transfectants is elicited, at least in part, through activation of the PI3/Akt signaling pathway in bladder carcinoma cells.
Results

Correlation of cadherin profiles and bladder carcinoma cell invasion
Previously, we have reported that bladder carcinoma cell lines exhibit three different cadherin profiles. Some expressed E-cadherin but not N-cadherin, others expressed E-and N-cadherin while a third group expressed N-but not E-cadherin (Gee et al., 1998) . To assess whether the cadherin profile in bladder carcinoma cell lines correlated with invasive potential, in vitro Matrigel invasion assays were performed with cell lines from the three groups displaying different cadherin profiles. The results in Figure 1 show that cell lines expressing Ecadherin but no N-cadherin (RT112, CUBIII and HT1376) were the least invasive, while cell lines expressing both E-and N-cadherin (HU456, 5637) displayed a low to moderate invasive potential. In contrast, cell lines expressing N-cadherin, but no Ecadherin (UM-UC-3, TCCSUP, J82), were the most invasive. Although there is some variation in the invasive potential within the groups, the ability to invade in this assay was highest in cells expressing N-, but not E-cadherin.
Preparation of N-cadherin-transfected bladder carcinoma cell lines
To determine whether the invasive potential correlated with, or was a result of, N-cadherin expression by these cells, N-cadherin was stably transfected into two bladder cell lines, CUBIII and HT1376 that express E-cadherin but not N-cadherin. Cells were cotransfected with Ncadherin and the puromycin resistance gene or puromycin alone followed by selection of transfectants in puromycin. Surviving colonies were ring cloned and screened for the expression of N-cadherin in Western blot analysis using an N-cadherin-specific antibody. By immunocytochemistry, we did not detect N-cadherin in puromycin control cells (Figure 2a, 2c) , but confirmed the presence of N-cadherin at the cell membrane in both transfected CUBIII and HT1376 cells (Figure 2b 
N-cadherin enhances the invasive potential of bladder carcinoma cells
The invasive potential of bladder carcinoma cell lines expressing N-cadherin was determined by the in vitro Matrigel invasion assays employing three puromycin controls and the three transfectants expressing the highest Previous studies employing breast carcinoma cells have shown that N-cadherin and FGF-2 cooperate to activate the MAPK pathway thereby resulting in tumor cell invasion (Suyama et al., 2002) . Thus, the effects on the MAPK pathway in response to FGF-2 were analysed in the bladder. CUBIII and HT1376/N-cadherin transfectants expressing the highest level of N-cadherin were serum-starved for 18 h followed by treatment for 18 h with or without 50 ng/ml FGF-2 in the presence of 5 mg/ml heparin. The levels of pMAPK, total MAPK, N-cadherin and c-myc levels were assessed (Figure 3c , d). FGF-2 treatment resulted in increased phosphorylation of MAPK in both CUBIII and HT1376 control and Figure 2 Characterization of CUBIII and HT1376/N-cadherin transfectants. Immunocytochemistry demonstrating lack of Ncadherin expression in puromycin (a and c, respectively) transfectants and membranous N-cadherin in CUBIII and HT1376/ N-cadherin transfectants (b and d, clones 3 and 5, respectively). Magnification is X200. Western blot analysis of N-and E-cadherin and b-and g-catenin in CUBIII (e) and HT1376 (f) puromycin and N-cadherin transfectants. Note the highest expressing CUBIII and HT1376/N-cadherin transfectants are clones 3 and 5, respectively. In vitro invasion assay performed on three puromycin and three N-cadherin clones for CUBIII (g) and HT1376 (h). All N-cadherin transfectants displayed an enhanced invasive capacity over control cells. Addition of the N-cadherin function blocking, GC-4, antibody inhibited invasion in a dose-dependent manner in both CUBIII and HT1376 transfectants (i) but not in either of the puro controls. Numbers are expressed as percent control where invasion in control puro lines was considered 100%. The data shown are the mean ( þ s.e.m.) of one experiment performed in triplicate N-cadherin transfectants. The MEK1 inhibitor, PD98059, reduced the level of pMAPK in the presence and absence of FGF-2 indicating that FGF-2 activated MAPK in both bladder cell lines.
Expression of c-myc was also increased with the addition of FGF-2 in the CUBIII puromycin-resistant control and its N-cadherin transfectants, but not in control or HT1376/N-cad transfectants suggesting that the signaling pathway linking MAPK to c-myc is compromised in HT1376 cells but intact in CUBIII cells. The MEK1 inhibitor did not alter c-myc levels in any of the cells tested and none of the treatments in either CUBIII or HT1376 affected N-cadherin levels.
HT1376/Nad clone 5 and CUBIII/N-cad clone 3 cells exhibited a high invasive potential in the absence of FGF-2 while treatment with FGF-2 or PD98059 had no significant effect on their invasive potential (Figure 3e,  f) . Surprisingly, when CUBIII/N-cad cells were treated with FGF and PD98059, their invasive potential was reduced in repeated assays. This treatment did not alter the invasive potential of HT1376/N-cad cells thereby suggesting that it is not elicited by N-cadherin (see also the decrease in control HT1376 puro cells).
A role for the PI3/AKT pathway in N-cadherin signaling
In search of alternative signaling pathways involved in N-cadherin-mediated invasion of bladder carcinoma cell lines, we investigated signaling pathways previously implicated in tumor cell invasion. Invasion assays were performed in the presence of DMSO (control), the MEK inhibitor PD98059, the p38 inhibitor SB203580 and the PI3 kinase inhibitor LY294002. Analysis of the effect of these inhibitors on the invasive potential of the highest N-cadherin CUBIII and HT1376 (Figure 4 ) expressors showed that their invasive potential was not altered by MEK or p38 inhibitors. In contrast, the PI3 kinase inhibitor reduced the invasive capacity of CUBIII and HT1376/N-cadherin transfectants by approximately 40% but did not alter invasion in either of the puro controls.
One of the downstream substrates of PI3 kinase is Akt, a molecule that has been implicated in multiple roles in tumorigenesis, including invasion (Tran et al., 2002; Arboleda et al., 2003; Grille et al., 2003) and N-cadherin-mediated apoptosis . Western blot analysis revealed increased phosphorylation of Akt associated with N-cadherin expression in both bladder cell lines ( Figure 5 ). Interestingly, the activation of Akt was more dramatic in the CUBIII transfectants that express more N-cadherin than the HT1376 transfectants. These results suggest that transfection of N-cadherin in E-cadherin expressing bladder carcinoma cell lines leads to increased phosphorylation of Akt possibly via the PI3 kinase pathway. Next, we inhibited Akt and examined its effects on the invasive potential of N-cadherin transfectants. Both CUBIII and HT1376/N-cadherin transfectants were treated with the Akt inhibitor for 17 h prior to the invasion assay. The results shown in Figure 6a demonstrate that the Akt inhibitor reduced the levels of pAkt in both CUBIII and HT1376/N-cadherin transfectants and the invasive potential of the CUBIII transfectants by 57% and HT1376 transfectants by 63% (Figure 6b ).
Since previous studies by Chen et al. (2001) demonstrated that Akt is a direct substrate of src and inhibition of src family kinases reduces the phosphorylation of Akt, we treated CUBIII and HT1376/N-cad transfectants with PP2, a selective inhibitor of src family kinases. We found that PP2 reduced the phosphorylation of Akt in both transfectants (Figure 6a ) accompanied by a reduction in their invasive capacity to 32 and 53% of control in CUBIII and HT1376/N-cad transfectants, respectively (Figure 6b ). Neither the AKT inhibitor nor PP2 altered the invasive capacity of the CUBIII or the HT1376 puro cells.
Inhibition of constitutively activated Akt in highly invasive bladder cells
UM-UC-3 and J82 are highly invasive bladder carcinoma cell lines expressing N-cadherin but no E-cadherin. Both cells lines lack PTEN expression owing to homozygous deletion of the gene (Wang et al., 2000) and consequently display constitutively activated Akt signaling. To examine whether Akt signaling plays an important role in the invasion of these cell lines, invasion assays were performed in the presence of LY294002, Akt inhibitor and also in the presence of PP2. The results shown in Figure 7 demonstrate a decrease in the invasive potential of J82 and UM-UC-3 cells in the presence of all three inhibitors as compared to control. These results suggest that the PI3/Akt pathway is involved in determining the invasive potential of bladder carcinoma cell lines.
Discussion
In previous work, we have reported novel expression of N-cadherin in bladder carcinoma cell lines (Gee et al., 1998) both studies, the expression of N-cadherin was closely linked to the invasive phenotype suggesting that Ncadherin, unlike E-cadherin (Frixen et al., 1991; Vleminckx et al., 1991) , does not play an invasive suppressor role in bladder cancer. To investigate the possible role of N-cadherin expression in bladder tumorigenesis, we stably transfected N-cadherin into two bladder epithelial cell lines lacking expression of this cadherin family member. In both cases, N-cadherin expression increased their invasive potential and this capacity was suppressed, in a dose-dependent manner, by a function-blocking N-cadherin antibody and inhibitors of the PI3 kinase pathway. These results imply that N-cadherin has a key role in determining the invasive capacity of bladder carcinoma cells via activation of PI3 kinase/Akt signaling.
Novel expression of N-cadherin in tumors has now been reported in squamous cell carcinoma of the head and neck, melanomas, bladder and prostate tumors (Hsu et al., 1996; Islam et al, 1996; Gee et al., 1998; Sanders et al., 1999; Tomita et al., 2000) . Our conclusions on the role for N-cadherin in establishing the invasive phenotype in bladder carcinoma cells are similar to those reported in breast carcinoma cell lines (Nieman et al., 1999; Hazan et al., 2000) , but differ in the signaling events elicited by N-cadherin expression (Suyama et al., 2002) . It is of note that there are a number of differences between breast and bladder carcinomas cells including the cadherin expression profiles. In breast carcinoma cell lines, N-cadherin and cadherin-11 were identified in invasive cell lines, where aberrant expression of these cadherin members is recorded in the absence of E-cadherin expression (Nieman et al., 1999) . This mutual exclusivity of E-and N-cadherin recorded in breast cell lines (Hazan et al., 1997) is not observed in bladder carcinoma cell lines (Gee et al., 1998) . Also, we found no evidence for the expression of cadherin-11 in neoplastic progression in the bladder (Gee et al., 1998) but recorded coexpression of E-, P-and N-cadherin in human tumor tissue (RiegerChrist et al., 2001) . This may prove important since, in the analysis of different parameters of change associated with N-cadherin expression in bladder carcinoma cells, we have selected transfectants expressing the highest levels of N-cadherin, comparable to the levels of Ecadherin detected in these same cells. In early experiments, using transfectants expressing lower levels of N-cadherin, no significant changes in invasive behavior were detected. This observation suggests that threshold levels of N-cadherin expression were required to enhance the invasive phenotype in these cells. The threshold level of N-cadherin required to elicit detectable invasive behavior is likely relative to the E-cadherin expression levels in the same cell, although our experiments do not address this point. Hence, the relative expression levels between cadherins in carcinoma cells may be a primary determinant of their invasive phenotype.
Studies investigating the signaling events linked to Ncadherin expression in bladder carcinoma cells initially focused on MAP kinase . Our experiments revealed that MAPK was activated in N-cadherin transfectants of CUBIII cells but was inactivated in HT1376 transfectants, suggesting that this pathway may not be involved in N-cadherin-mediated invasion in bladder carcinoma cells. An alternative explanation could be that MAP kinase signaling was disrupted in HT1376 cells. Exposure of transfectants to FGF-2 however, did not alter the invasive behavior in either control or N-cadherin expressing lines while leading to activation of MAPK in both with c-myc expression elevated only in CUBIII cells. This suggests a discontinuity in signaling between MAPK and c-myc regulators in HT1376 cells. Although the MEK1 inhibitor, PD98059, blocked activation of MAPK in these cells, no change in the invasive potential of bladder cells resulted. Interestingly, but inexplicably, addition of FGF-2 and PD98059 to CUBIII/N-cadherin transfectants repeatedly resulted in significantly reduced invasion. Overall, our results were similar in both bladder carcinoma cells lines but differed from those obtained with breast carcinoma cells, where FGF-2 increased the invasive potential of N-cadherin transfectants (Suyama et al., 2002) .
To investigate the possible involvement of alternative signaling pathways in N-cadherin-mediated invasion events, we utilized biochemical inhibitors of MEK1, p38 and PI3 kinase in in vitro invasion assays. Although all of the signaling pathways blocked by the aforementioned inhibitors have been implicated in invasion of different cells (Westermarck and Kahari, 1999; Sotsios and Ward, 2000; Chang and Karin, 2001) , only blockade of the PI3 kinase pathway altered invasion in N-cadherin transfectant bladder carcinoma cells. Studies on downstream targets of PI3 kinase revealed that Akt was more highly phosphorylated at serine-473, the hallmark of Akt activation, in N-cadherin expressing cells. In addition, an Akt inhibitor reduced serine-473 phosphorylated Akt in N-cadherin transfectants and the invasive potential of these cells. These results suggest that N-cadherin promotes invasion, at least in part, through activation of the Akt signaling pathway. Although the intermediary signals between N-cadherin and Akt have not been identified, N-cadherin-mediated invasion and Akt activation was reduced in the presence of a PI3 kinase inhibitor, suggesting that PI3 kinase is a regulator of Akt phosphorylation in this pathway.
The involvement of Akt signaling in the invasion potential was addressed using two human bladder carcinoma cell lines that display activated Akt and are highly invasive in in vitro assays. These cell lines, J82 and UM-UC-3, express N-cadherin in the absence of Ecadherin and lack PTEN protein due to homozygous deletion of the gene (Wang et al., 2000) . The PI3 kinase inhibitor (LY294002) and the Akt inhibitor both reduced invasion, further implicating the Akt signaling pathway as a primary event in invasive bladder cell behavior. Although the Akt inhibitor decreased invasion to approximately 50% in both cell lines, the PI3 kinase inhibitor does much better at inhibiting invasion in UM-UC-3 cells as compared to J82 cells. One possible explanation is that J82 may have higher levels of PI3 kinase than does UM-UC-3, thereby making it more difficult to decrease the activity of this enzyme.
Surprisingly, a selective inhibitor of src family tyrosine kinases, PP2, showed a similar invasiveinhibitory effect in both N-cadherin transfectants and the aforementioned bladder cell lines. PP2 has featured mainly in the colorectal cancer arena where there is substantive evidence that the activation of src family members, specifically pp60c-src, contribute to neoplastic progression (Cartwright et al., 1989 (Cartwright et al., , 1990 Talamonti et al., 1993) . Since no such evidence exists in bladder (Fanning et al., 1992) it seemed counterintuitive that PP2 would have an effect in bladder cancer. We found however, that PP2 was as potent as the PI3 kinase and the Akt inhibitor in suppressing invasion and effectively reduced the phosphorylation of Akt on serine-473. Src family protein tyrosine kinases can alter the function of PTEN to regulate PI3/Akt cascades (Lu et al., 2003) , but the absence of PTEN in J82 and UM-UC-3 cells suggest an alternative route of regulation by PP2 in these cells. A recent report suggests that tyrosine phosphorylation is required for Akt activation that can be mediated directly by src kinases (Chen et al., 2001) .
A role for Akt in tumorigenesis is inferred from its involvement in growth regulatory events to promote and/or suppress signals, programmed cell death, angiogenesis, invasion and metastasis (Testa and Bellacosa, 2001; Paez and Sellers, 2003) . The invasive and metastatic potential is stimulated by the secretion of matrix metalloproteinases (Thant et al., 2000) and the activation of Akt was shown to enhance motility and invasion in a squamous epithelial cell line and is accompanied by an epithelial to mesenchymal transition (Grille et al., 2003) . This Akt-mediated transition resulted in downregulation of E-cadherin and modulation in expression of additional cadherin/catenin components. In our study however, we did not detect changes in this adhesion complex following modulation of Akt activity in different bladder carcinoma cells (data not shown).
In summary, we have shown that introduction of Nto E-cadherin-expressing bladder carcinoma cells increases the phosphorylation level of Akt via the PI3 kinase pathway that ultimately leads to an increased invasive capacity. Blockade of both the PI3 kinase and Akt signaling pathways inhibited N-cadherin-mediated invasive. In this way, the Akt signaling pathway(s) may represent potential therapeutic target(s) for treating late-stage bladder cancer.
Materials and methods
Cell culture
Human bladder cell lines RT112, HU456, 5637, HT1376, CUBIII, UM-UC-3 and J82 (ATCC) and TCCSUP (kindly provided by Dr C Reznikoff) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 7.5% fetal bovine serum and penicillin/streptomycin.
Transfection
HT1376 and CUBIII cells were plated at 3 Â 10 5 cells per 60 mm dish 24 h before lipofection. Either the puromycin resistance gene alone or the N-cadherin construct (Levenberg et al., 1998) plus the puromycin-resistance gene were mixed with lipofectin reagent (Gibco BRL, Gaithersburg, MD, USA) and incubated with cells at 371C overnight in the absence of serum. Following incubation, cells were washed and maintained in standard medium. At 48 h post-transfection, cells were split into puromycin-containing medium (2 mg/ml) to select successfully transfected colonies. Individual colonies screened for drug selection were ring cloned 2 weeks later.
Antibodies and inhibitors
The following antibodies were used in this study: N-cadherin, clone 13A9 (kindly provided by Dr M Wheelock, Toledo, OH, USA); N-cadherin, a-catenin, g-catenin, b-catenin, and p120 (Transduction Laboratories, Lexington, KY, USA); c-myc (Oncogene Research Products, Boston, MA, USA); MAPK, phosphorylated MAPK, Akt and phosphorylated Akt (Cell Signaling Technology, Beverly, MA, USA); E-cadherin (Zymed, San Francisco, CA, USA); N-cadherin function blocking antibody, GC-4 (Sigma, St Louis, MO, USA). All biochemical inhibitors were purchased from Calbiochem (San Diego, CA, USA).
Western blot analysis
Subconfluent dishes of cells were washed in phosphatebuffered saline (PBS) followed by lysis in hot sample buffer (2 Â ESB -0.08 M Tris, pH 6.8; 0.07 M SDS, 10% glycerol, 0.001% bromophenol blue and 1 mM CaCl 2 ) and sheared through a 26-gauge needle. Lysates were then assayed for protein concentration using the BSA method (Pierce, Rockford, IL, USA). After determination of protein content, b-mercaptoethanol (1%) was added to each sample. Samples were boiled for 5 min and protein was loaded in each lane of a 7.5% or 12.5% polyacrylamide gel. Proteins were transferred overnight onto nitrocellulose. Membranes were blocked in 10% milk in TBS with 0.05% Tween (TBST) and placed on primary antibody overnight at 41C. Blots were washed in TBST, three times for 15 min each, and secondary antibody linked to horseradish peroxidase was incubated with the blots for 60 min at room temperature. Blots were then washed as described above and developed with an ECL kit (Amersham, Arlington Heights, IL, USA). For experiments involving the addition of FGF-2, cells were serum-starved for 18 h followed by treatment for 18 h with or without 50 ng/ml FGF-2 in the presence of 5 mg/ ml heparin and in the presence or absence of 40 mM PD98059. For additional experiments, cells were pretreated with inhibitors for either 1 (PD98059-40 mM, SB203580-20 mM, LY294002-20 mM and PP2-5 mM) or 17 h (Akt inhibitor; 1L-6-Hydroxymethylchiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate-20 mM) prior to washing in PBS and lysing.
Invasion assays
In vitro invasion assays were carried out using modified Boyden chambers consisting of Transwell (8 mm pore size; Corning Costar Corp., Cambridge, MA, USA) membrane filter inserts in 24-well tissue culture plates. The upper surfaces of the membranes were coated with Matrigel (Collaborative Biomedical Products, Bedford, MA, USA) and placed into 24-well tissue culture plates containing 600 ml of NIH/3T3 conditioned media (experimental) or plain DMEM (control). Cells (1 Â 10 5 ) were added to each Transwell chamber and allowed to invade toward the underside of the membrane for 5 (J82), 12 (HT1376) or 14 h (CUBIII and UM-UC-3) at 371C. Cells that pass through the membrane were fixed in methanol, stained with crystal violet and counted under a light microscope. In additional assays, the cells were preincubated for either 1 (PD98059-40 mM, SB203580-20 mM, LY294002-20 mM, PP2-5 mM and GC-4-1:50 or 1:10) or 17 h (Akt inhibitor;
1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-Omethyl-3-O-octadecylcarbonate-20 mM) before addition to the Matrigel-coated wells. All assays were performed in triplicate and repeated three times.
Immunocytochemical analysis
Cells were grown on glass slides, washed with PBS and fixed in 3.7% formaldehyde for 15 min at room temperature. Cells were then rinsed in three changes of PBS and permeabilized in 0.5% Triton X-100 in PBS. Following three washes in PBS, cells were stained for N-cadherin (Transduction Laboratories, Lexington, KY, USA) using an automated immunohistochemical processor (Model 320; Ventana Medical Systems, Tucson, AZ, USA).
